Epigenetic Priming with Oral Decitabine/Cedazuridine Combined with Nivolumab in Unresectable or Metastatic Mucosal Melanoma: Clinical and Correlative Findings from a Phase Ib/II Trial. [PDF]
Borgers JSW +13 more
europepmc +1 more source
Epigenetic Modulation of Thyroid-Stimulating Hormone Receptor Expression in Orbital Fibroblasts From Graves' Ophthalmopathy: Target for Treatment. [PDF]
Chompoowong R +9 more
europepmc +1 more source
Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes. [PDF]
Lyu C +6 more
europepmc +1 more source
Gastrointestinal adverse reactions and metabolism-nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis. [PDF]
Xiang M +8 more
europepmc +1 more source
Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain. [PDF]
Lloret Avellá M +3 more
europepmc +1 more source
Correction: Decitabine attenuates ischemic stroke by reducing astrocytes proliferation in rats. [PDF]
PLOS One Staff.
europepmc +1 more source
Pharmacoepigenetics: from epigenetic regulation to personalized therapeutics. [PDF]
Nguyen AM, Fandy TE.
europepmc +1 more source
Decitabine induces cell differentiation and growth inhibition accompanied by upregulation of microRNA-143 and MS4A3 in the myelodysplastic syndromes-derived leukemic cell line MDS-L. [PDF]
Nishi R +3 more
europepmc +1 more source
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE). [PDF]
Issa GC +31 more
europepmc +1 more source
Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance. [PDF]
Zhou Q +4 more
europepmc +1 more source

